Last reviewed · How we verify
Dabigatran + Ticagrelor
Dabigatran + Ticagrelor is a Anticoagulant + antiplatelet agent combination Small molecule drug developed by Zuyderland Medisch Centrum. It is currently FDA-approved for Acute coronary syndrome with dual anticoagulant-antiplatelet therapy.
This combination uses dabigatran (a direct thrombin inhibitor) and ticagrelor (a P2Y12 platelet inhibitor) together to provide dual anticoagulant and antiplatelet effects for thrombotic prevention.
Dabigatran and Ticagrelor are used in combination to treat conditions such as atrial fibrillation and acute ischemic stroke, as well as in patients who have undergone percutaneous coronary intervention. Ticagrelor works as a small molecule negative allosteric modulator of the P2Y purinoceptor 12, a type of purinergic receptor.
At a glance
| Generic name | Dabigatran + Ticagrelor |
|---|---|
| Sponsor | Zuyderland Medisch Centrum |
| Drug class | Anticoagulant + antiplatelet agent combination |
| Target | Thrombin (Factor IIa) and P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Dabigatran directly inhibits thrombin (Factor IIa), blocking the final step of the coagulation cascade and preventing clot formation. Ticagrelor irreversibly blocks the P2Y12 adenosine diphosphate receptor on platelets, preventing platelet aggregation. Together, they provide complementary anticoagulant and antiplatelet mechanisms for enhanced thrombotic protection in acute coronary syndromes or high-risk cardiovascular conditions.
Approved indications
- Acute coronary syndrome with dual anticoagulant-antiplatelet therapy
Common side effects
- Bleeding (major and minor)
- Dyspnea
- Bradycardia
- Gastrointestinal bleeding
Key clinical trials
- Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.
- Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG (PHASE3)
- Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study
- Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis (NA)
- Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4) (PHASE4)
- Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI (PHASE4)
- Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI (PHASE4)
- Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dabigatran + Ticagrelor CI brief — competitive landscape report
- Dabigatran + Ticagrelor updates RSS · CI watch RSS
- Zuyderland Medisch Centrum portfolio CI
Frequently asked questions about Dabigatran + Ticagrelor
What is Dabigatran + Ticagrelor?
How does Dabigatran + Ticagrelor work?
What is Dabigatran + Ticagrelor used for?
Who makes Dabigatran + Ticagrelor?
What drug class is Dabigatran + Ticagrelor in?
What development phase is Dabigatran + Ticagrelor in?
What are the side effects of Dabigatran + Ticagrelor?
What does Dabigatran + Ticagrelor target?
Related
- Drug class: All Anticoagulant + antiplatelet agent combination drugs
- Target: All drugs targeting Thrombin (Factor IIa) and P2Y12 receptor
- Manufacturer: Zuyderland Medisch Centrum — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome with dual anticoagulant-antiplatelet therapy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing